ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Istaroxime

Also written as “istaroxime”.

Its studies are mostly in Heart Failure · Shock, Cardiogenic, led by 5 companies.

Drug pageIstaroxime: every studyMany companies study it; this page follows only the 8 they lead. All 9 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Jul 9, 20158 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Windtree Therapeutics31 open or runningphase 2since Jul 9, 2015Jul 9, 2015none ahead
Debiopharmits history only20 open or runningphase 2since Feb 5, 2009Feb 5, 2009none ahead
Lee's Pharmaceuticalits history only10 open or runningphase 1since Jun 17, 2015Jun 17, 2015none ahead
Seismic Pharmaceuticals Operationsits history only11 open or runningphase 3since May 1, 2026May 1, 2026Dec 2028phase 3 · NCT07583446
sigma-tau i.f.r.its history only10 open or runningphase 2since Feb 5, 2008Feb 5, 2008none ahead

Also a collaborator on its studies: CVie Therapeutics, Momentum Research and MDS Pharma Services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Windtree Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 9, 2015First study: phase 2 study in Acute Decompensated Heart FailureFirst studyNCT02617446 · 120 enrolled · China, Italy
  2. Mar 24, 2020Phase 2 study in Shock, CardiogenicNCT04325035 · 90 enrolled · United States, Argentina, Italy and more
  3. Jul 26, 2023Phase 2 study in Shock, CardiogenicNCT05975021 · 20 enrolled · United States, Argentina, Israel and more

TargetBeta

“Sodium/potassium-transporting ATPase inhibitor; Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator”ChEMBL 37, by rule

Studies

All 3 Windtree Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05975021Shock, Cardiogenic · United States, Argentina, Israel and more2Active, not recruitingJul 28, 202520
NCT04325035Shock, Cardiogenic · United States, Argentina, Italy and more2CompletedSep 26, 202490
NCT02617446Acute Decompensated Heart Failure · China, Italy2CompletedAug 14, 2018120

How it is read

Names in the registry

  • “Istaroxime”, 13 entries
  • “istaroxime”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.